GX-03 Phase is a Turn Therapeutics Inc. program in moderate to severe atopic dermatitis. Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Moderate to severe atopic dermatitis. Sponsor: Turn Therapeutics Inc. (TTRX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for GX-03 Phase is a Readout in Q1 2027.
No FDA decision for GX-03 Phase is in our archive yet.
In our records GX-03 Phase is under review or in development for Moderate to severe atopic dermatitis.
Turn Therapeutics Inc. (TTRX).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.